Predicting outcomes for people with cardiovascular-kidney-metabolic syndrome
A Prospective Cohort Study on Prognostic Factors in Patients With Cardiovascular-kidney-metabolic Syndrome
Peking University Third Hospital · NCT07327606
This project will test whether blood-based molecular markers and heart imaging can help predict outcomes for people with cardiovascular-kidney-metabolic syndrome.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 4526 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | Peking University Third Hospital (other) |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT07327606 on ClinicalTrials.gov |
What this trial studies
This prospective cohort will enroll patients with cardiovascular-kidney-metabolic syndrome and collect clinical data, plasma, and whole blood for transcriptomic, proteomic, and metabolomic analysis. Participants will undergo adenosine stress echocardiography to gather detailed cardiac function data and will be followed long term for clinical outcomes. Modern information technology and bioinformatics will be used to link biomarkers and imaging with prognosis and to build a predictive model that combines molecular and clinical information. The goal is to refine risk stratification and guide personalized treatment and follow-up strategies for CKM patients.
Who should consider this trial
Good fit: Adults meeting criteria for CKM stages 0–4 with complete clinical data who can undergo adenosine stress echocardiography and regular follow-up are the intended participants.
Not a fit: Patients with active infections, autoimmune disease, cancer, life expectancy under two years, known adenosine hypersensitivity, inability to follow up, or who are pregnant or breastfeeding are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the work could allow clinicians to better predict who is at higher risk and tailor treatments and follow-up for people with CKM.
How similar studies have performed: Related biomarker and imaging studies in heart, kidney, and metabolic diseases have shown promise, but integrating multi-omics with stress echocardiography for CKM prognosis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1）Patients who meet the criteria for CKM stages 0-4 were included. 2）Clinical data were complete. Exclusion Criteria: * 1\) Presence of infectious diseases during the sample retention period. 2) Presence of autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, vasculitis, etc. 3\) Presence of tumors. 4) Patients with an estimated life expectancy of less than 2 years. 5) Patients with known hypersensitivity to adenosine. 6) Patients who cannot follow up regularly. 7) Pregnant or breastfeeding women, and those participating in other clinical trials.
Where this trial is running
Beijing, Beijing Municipality
- Peking University Third Hospital — Beijing, Beijing Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Shengjia Peng
- Email: 819178014@qq.com
- Phone: 13020535029
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Patient With Cardiovascular-kidney-metabolic Syndrome